Earlier, Pfizer said that the final analysis of the Phase 3 trial showed that the vaccine had 95 percent efficacy and reported "no serious safety concerns."

When speaking at a virtual briefing of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on December 8, Pfizer CEO Albert Bourla said that the COVID-19 vaccine development saw "politicisation," warning against having a discussion on vaccines "in political rather than in scientific terms."